Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral
Tweet
Share
E-mailGet Alerts ATRS Hot Sheet
Price: $5.59 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).
For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.
Shares of Antares Pharma closed at $5.58 yesterday.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Old Dominion Freight Line (ODFL) PT Raised to $233 at TD Cowen
- Suntory Beverage & Food Ltd (2587:JP) (STBFY) PT Lowered to JPY4,600 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
